Clinical trials: Nonarteritic Anterior Ischemic Optic Neuropathy
Triamcinolone Acetonide, Optic Neuropathy, Ischemic
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION
NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion of the short ciliary arteries that supply it.
- Trial name
- NCT02329288
- Testing
- Triamcinolone Acetonide
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Non Arteritic Anterior Ischemic Optic Neuropathy
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population.
- Trial name
- NCT02341560
- Testing
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg
- Where
- 85 sites in United States, Australia and 6 more
- Volunteers
- 732 people
- Sponsor
- Quark Pharmaceuticals
Nonarteritic Anterior Ischemic Optic Neuropathy
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study
This prospective randomized clinical study aims to evaluate the efficacy and safety of autologous platelet-rich plasma (PRP) injection in patients with acute non-arteritic anterior ischemic optic neuropathy (NAION).
- Trial name
- PRP-NAION (NCT07330713)
- Testing
- Autologous Platelet-Rich Plasma (PRP)
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Uludag University
Acute Nonarteritic Anterior Ischemic Optic Neuropathy
Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo
In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn in less than 30 days without…
- Trial name
- NCT01330524
- Testing
- Avastin and Triamcinolone
- Where
- Iran
- Volunteers
- 16 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Obstructive Sleep Apnea (OSA), Ischemic Optic Neuropathy/Optic Nerve Stroke
Optic Nerve Injury in Obstructive Sleep Apnea Patients
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries.
- Trial name
- NCT06748703
- Testing
- CPAP Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanjing Medical University
Non Arteritic Ischemic Optic Neuropathy
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
- Trial name
- Ampyra (NCT01975324)
- Testing
- dalfampridine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Neuro-Ophthalmologic Associates, PC
Nonarteritic Anterior Ischemic Optic Neuropathy
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION.
- Trial name
- NCT03547206
- Testing
- RPh201 Cohort A, RPh201 Cohort B
- Where
- 15 sites in United States
- Volunteers
- 165 people
- Sponsor
- Regenera Pharma Ltd
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Nonarteritic Anterior Ischemic Optic Neuropathy
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
- Trial name
- NAION (NCT00561834)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Nonarteritic Anterior Ischemic Optic Neuropathy
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION).
- Trial name
- NCT00432393
- Testing
- levodopa-carbidopa
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Nonarteritic Anterior Ischemic Optic Neuropathy
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
Study H6D-MC-LVHQ is an observational, non-interventional, multi-center, prospective, case-crossover study to evaluate the possible association between the use of phosphodiesterase type 5 (PDE5) inhibitors and the risk of acute…
- Trial name
- NCT01131104
- Testing
- PDE5 Inhibitors
- Where
- 44 sites in United States
- Volunteers
- 345 people
- Sponsor
- Eli Lilly and Company